Skip to Main Content

Skip Nav Destination

Article navigation

Research Watch| May 02 2022

Ruxolitinib with Navitoclax Is Efficacious and Safe in Myelofibrosis

Author & Article Information

Online Issn: 2159-8290

Print Issn: 2159-8274

©2022 American Association for Cancer Research

2022

American Association for Cancer Research

Cancer Discov (2022) 12 (5): OF4.

https://doi.org/10.1158/2159-8290.CD-RW2022-037

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.